Condition: Hiv · Sponsor: University Hospital, Caen
The goal of this pilot, phase 2, single-arm, clinical trial is to assess the antiretroviral combination Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF) in participants with suppressed HIV who previously developed M184V/I mutation that confers resistance to 3TC. The main question it aims to answer is to explore the rate of HIV suppression 24 weeks after the switch to DOR/3TC/TDF. The study follow-up will continue until 48 weeks. Other endpoints will be metabolic changes, weight changes, modification in the HIV-DNA mutations overtime. Eligible participants will switch from their prior regimen to DOR/3TC/TDF with careful HIV-RNA monitoring.
This description comes directly from the study's public registry record.
Jean-Jacques Parienti, MD, PhD · +33231064320 · parienti-jj@chu-caen.fr
Francois Fournel, MSc · fournel-f@chu-caen.fr
Always discuss trial participation with your own doctor first.
| CHU de Caen | Caen, France | Recruiting |
| CHU Orléans | Orléans, France | Recruiting |
| CHU Rouen | Rouen, France | Recruiting |
| CH Tourcoing | Tourcoing, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06034938